Journal article
Long-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis
EB Suhler, GJ Jaffe, E Fortin, LL Lim, PT Merrill, AD Dick, AP Brezin, QD Nguyen, JE Thorne, J Van Calster, L Cimino, A Adan, H Goto, T Kaburaki, M Kramer, AT Vitale, M Kron, AP Song, J Liu, S Pathai Show all
Ophthalmology | ELSEVIER SCIENCE INC | Published : 2021
Abstract
Purpose: To evaluate long-term efficacy and safety of extended treatment with adalimumab in patients with noninfectious intermediate, posterior, or panuveitis. Design: Open-label, multicenter, phase 3 extension study (VISUAL III). Participants: Adults who had completed a randomized, placebo-controlled phase 3 parent trial (VISUAL I or II) without treatment failure (inactive uveitis) or who discontinued the study after meeting treatment failure criteria (active uveitis). Methods: Patients received subcutaneous adalimumab 40 mg every other week. Data were collected for ≤ 362 weeks. Adverse events (AEs) were recorded until 70 days after the last dose. Main Outcome Measures: Long-term safety and..
View full abstractGrants
Awarded by AbbVie
Funding Acknowledgements
Sponsored by AbbVie, Inc., North Chicago, Illinois. The sponsor participated in study design and conduct; data management, analysis, and interpretation; and manuscript preparation, review, and approval. Medical writing support was provided by Catherine DeBrosse, PhD, of ICON (North Wales, PA), and was funded by AbbVie Inc.